Trial Profile
Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Dec 2021 Results (data cutoff date January 20, 2019) assessing the modified weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) regimen in pretreated patients with advanced non-small cell lung cancer, published in the American Journal of Clinical Oncology.
- 07 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2014 New trial record